With early initiation of atorvastatin 80 mg plus ezetimibe 10 mg, and escalation with bempedoic acid or PCSK9i if needed, all 85 patients hospitalized for STEMI achieved the 2019 ESC/EAS Guidelines LDL-c target.
The goal of LDL-c management is to reduce long-term CVD risk. Statins form the foundation of lipid-lowering therapy, but more ammunition is needed to attain LDL-c goals in all patients. This series of 3 presentations discusses current and evolving therapeutic LDL-c lowering options.
In a post-hoc analysis of 4 RCTs, a ≥30% LDL-c reduction with bempedoic acid was seen in 25% of statin-treated patients and in more than half of statin-naïve patients. Factors associated with this reduction were also assessed.
The Journal of the American College of Cardiology has published the 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk.
Where do novel therapies targeting the PCSK9 pathway might fit in with regard to the lipid management paradigm? Ann Marie Navar gives an overview on current and future therapies.
Prof. Ray explains why therapy for LDL-c lowering in very high-risk patients should become like BP-combination therapy.
There have been no direct comparative studies of inclisiran, evolocumab, alirocumab, bempedoic acid, and ezetimibe in patients with hypercholesterolemia and increased cardiovascular risk receiving maximal tolerated statin therapy. A network meta-analysis may provide further insight.
In a follow-up study of the CLEAR Harmony trial, up to 2.5 years of continuous treatment with bempedoic acid was generally well tolerated and stably decreased LDL-c levels in patients with ASCVD and/or heterozygous familial hypercholesterolemia.
Bempedoic acid has been approved by the FDA in 2020, but what is the potential place of bempedoic acid in the arsenal of lipid-lowering therapies? With question to test your knowledge.
ACC 2022 Two analyses using data of four phase 3 trials show that treatment with bempedoic acid lowers LDL-c in patients with renal impairment and in patients with hypertension. In addition, the analyses showed that bempedoic acid was generally well tolerated in these patients.
Real-world evidence shows that the majority of patients do not achieve their LDL-c target goals. Where do we fall short in the need for combination therapy?
ESC 2021 The SANTORINI study aims to investigate whether the 2019 ESC/EAS guidelines for the management of dyslipidemia are being implemented across Europe.